Recent Finacing
Recent Raise
SpecificiT Pharma develops cellular immunotherapies for hematological cancers by expanding donor T‑cells against selected minor histocompatibility antigens to eliminate cancer cells after allogeneic transplant; in Phase I AML study.
Focus Areas
Recent Investors
Funding round
Investors